Good evening :)
$
₹
Incannex Healthcare Ltd ADR

Incannex Healthcare Ltd ADR

IXHL

NASDAQ
Asset Logo

Incannex Healthcare Ltd ADR

IXHL

NASDAQ
$3.280.92% (+0.02)
$
₹
$3.280.92% (+0.02)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Micro Cap

With a market cap of $38.6M the stock is ranked 5207

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.53
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-16.62
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Company Profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
70.48
70.48
1Y Return
19.4%
19.4%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
24.45
24.45
1Y Return
41.48%
41.48%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
27.25%
27.25%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.76
30.76
1Y Return
32.43%
32.43%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.97
19.97
1Y Return
42.89%
42.89%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Incannex Healthcare Ltd ADR -0.53-
AbbVie Inc70.4850.450.35
Amgen Inc24.4518.181.89

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

0
-35.5
-6.4
-6.5
-3.8
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Revenue
Net Income
Financial YearQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Total Revenue-000.010.100.0100.06000
Net Income-0.72-9.28-6.46-7.98-3.96-3.96-35.57-6.40-6.52-3.88
Net Profit Margin12170.99%--53841.66%-7324.32%-20470.49%--53398.58%---
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Incannex Healthcare Ltd ADR (IXHL) share price today is $3.28 as of September 11, 2026 at 10:09 PM IST. The stock touched a day high of $3.29 and a day low of $3.21.

  2. Incannex Healthcare Ltd ADR stock trades on NASDAQ under the ticker symbol IXHL.

  3. Incannex Healthcare Ltd ADR's market capitalization is $38.64M as of September 11, 2026 at 10:09 PM IST.

  4. Incannex Healthcare Ltd ADR's price-to-earnings (P/E) ratio is N/A as of September 11, 2026.

  5. Incannex Healthcare Ltd ADR's price-to-book (P/B) ratio is 0.53 as of September 11, 2026.

  6. Yes, You can buy Incannex Healthcare Ltd ADR shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Incannex Healthcare Ltd ADR shares in three steps: 1. Search Incannex Healthcare Ltd ADR on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Incannex Healthcare Ltd ADR trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Incannex Healthcare Ltd ADR (IXHL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 3.0487 shares at the current price of $3.28.

Loading...